

# Moderne kardiale Bildgebung bei Verdacht auf KHK

**24. Birsecker Herzfortbildung, 29.01.2026**

**Prof. Dr. med. Ronny Ralf Büchel**

**FMH Kardiologie und Nuklearmedizin**

**LA / Stv. Klinikdirektor**

**Klinik für Nuklearmedizin**


**Universitätsspital Zürich**

# Disclosures

**Multimodality imager: CT, PET, SPECT, MRI**

Speaker honoraria from: Gilead and GE Healthcare




Research funding from: Swiss Heart Foundation and GE Healthcare



**70% stenosis in mid-LAD**  
**What now?**

# CCTA overestimates stenosis

# Stenosis ≠ Ischemia



False-positive findings in up to 35%

Arbab-Zadeh et al. *JACC Cardiovasc Imaging*. 2011 Feb;4(2):191-202.  
 Cheng et al. *JACC Cardiovasc Imaging*. 2008 Jul;1(4):460-71  
 Tonino et al. *FAME*. *J Am Coll Cardiol*. 2010 Jun 22;55(25):2816-21

# What to chose if everything (!) is available



**CT**



**Echo**



**SPECT**



**PET**



**MR**

# Stress echocardiography



# Stress Echocardiography

## Advantages

- Good diagnostic accuracy (good specificity, moderate sensitivity)
- No ionizing radiation exposure
- Relatively low costs

## Disadvantages

- Dependent on good acoustic window
- Dependent on operator

# Magnetic resonance imaging



# Stress CMR

## Advantages

- Combination of perfusion, tissue characterization and function
- Good diagnostic accuracy
- No ionizing radiation exposure

## Disadvantages

- Many contraindications
- Long protocols



# Cardiac SPECT





# Cardiac PET







# Nuklearkardiologie – Myokardperfusions-PET



# PET myocardial perfusion imaging - Semiquantitative



# PET With Superior Image Quality (at lower radiation dose)




**NH3-PET**

5.0 mSv

1.03 mSv

Male patient, 80y, BMI 23kg/m<sup>2</sup>


# PET myocardial perfusion imaging - Quantitative







Quantitative information

+

Semiquantitative information




# A picture is worth a thousand words But if you add numbers... you get increased sensitivity




# PET myocardial perfusion imaging

<sup>13</sup>N-NH<sub>3</sub> PET-MPI (semiquant)



<sup>13</sup>N-NH<sub>3</sub> PET-MPI (quantitative)



## Advantages

- Excellent image quality
- Routine blood flow quantification
- Excellent diagnostic accuracy
- Low radiation dose exposure (1-2mSv)
- No contraindications

## Disadvantages

- Cost
- Availability

	<sup>15</sup> O-Water	<sup>13</sup> N-Ammonia	<sup>82</sup> Rb
Isotope half-life (min)	2.03	9.97	1.27
Total dose for PET (mSv)	1.6-2.0	1.5-2.2	1.1-2.2
Rest-Stress interval (min)	0	30	0
Production method	Cyclotron (on-site)	Cyclotron (on-site)	Generator



# What do the guidelines recommend?

## CCTA

In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to diagnose obstructive CAD and to estimate the risk of MACE.

**I**

**A**

## Stress Echo

In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.

**I**

**B**

## Nuclear

In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, SPECT or, preferably, PET myocardial perfusion imaging is recommended to:

- diagnose and quantify myocardial ischaemia and/or scar;
- estimate the risk of MACE;
- quantify myocardial blood flow (PET).

**I**

**B**


## CMR

In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, CMR perfusion imaging is recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.

**I**

**B**

# Patient-centered approach



**Health Insurance** +  
Richard Smith  
The Richmond Corporation  
Dr. Susan Jones, Primary care  
(800)123-4567

Anatomic test to identify/exclude coronary plaque and stenosis, anomalous origin of coronary artery, identify other relevant diagnoses.

Functional test to confirm chest pain is anginal, evaluate physiologic response to exercise, guide revascularization, identify microvascular dysfunction.

**Multimodality mindset**  
**Multimodality approach**  
**Multimodality imagers**

Imaging should be based on

likelihood

Local expertise

- Patient characteristics
- Patient preference




A nighttime aerial photograph of a university campus. The buildings are illuminated from within, and a fountain in the foreground is lit with blue light. The sky is dark, and the overall scene is vibrant with city lights.

**Thank you!**

**[ronny.buechel@usz.ch](mailto:ronny.buechel@usz.ch)**


# Diverses



# Case







# Coronary CT angiography (CCTA)





**Obstructive CAD definitely excluded  
in less than 30 minutes and with <1mSv of radiation exposure**

# Prognostischer Wert: Kalzium-Score versus Koro-CT




n = 434


Follow-Up = 6.1 ± 0.6 Jahre

# Prognostische Wertigkeit der Koro-CT



n = 434; mittlerer Follow-up 47 ± 16 Wochen <sup>1</sup>



n = 405; medianer Follow-up 6.1 Jahre <sup>2</sup>




# CCTA overestimates stenoses




False-positive findings in up to 35%


# Ischemia versus stenosis





# CCTA overestimates stenoses




# CCTA overestimates stenoses




# Impact of plaque morphology on perfusion




# What do the guidelines recommend?



# Stenosis ≠ Ischemia



**Lesions-specific factors**




**Factors that affect myocardial blood flow**

**The functional significance of coronary lesions is determined by many factors**


# Prognostic benefit of revascularization depends on ischemic burden

SPECT

n = 14'627




n = 7'832






PET



n = 16'029



# Principle of Scintigraphy and SPECT



# SPECT myocardial perfusion imaging



## Advantages



- Widely available
- Good diagnostic accuracy
- No contraindications

## Disadvantages

- Image artifacts (attenuation)
- Radiation dose exposure (5-10mSv)
- Relative perfusion assessment


99mTc-Tetrofosmin SPECT-MPI

# Single-Photon-Emission-Computed-Tomography (SPECT)



**Dauer Bildakquisition: ca. 15-20 Minuten**  
**Strahlenbelastung: 8-10 mSv**

# SPECT mit Halbleiter-Detektoren aus Cadmium-Zink-Tellurit




Dauer Bildakquisition: **2-3 Minuten**<sup>1,2</sup>  
Strahlenbelastung: 4-6 mSv


**Moderne CZT-Kamera**

# PET Myokardperfusions-Tracer





<i>Tracer</i>	<i>Production</i>	<i>Half-life</i>
<b><math>^{15}\text{O}</math>-Water</b>	<b>Cyclotron</b>	<b>2 min</b>
<b><math>^{13}\text{N}</math>-Ammonia</b>	<b>Cyclotron</b>	<b>10 min</b>
<b><math>^{82}\text{Rb}</math></b>	<b>Generator</b>	<b>1 min</b>
<b><math>^{18}\text{F}</math>-Flurpiridaz*</b> <i>* currently in phase III study</i>	<b>Cyclotron</b>	<b>110 min</b>



# Myocardial perfusion PET - Semiquantitative (relative)



# Myocardial blood flow quantification



Best Fit:  
 $K_1 = 1.0 \text{ mL/min/cm}^3$   
 $k_2 = 5.0 \text{ min}^{-1}$   
 $k_3 = 0.2 \text{ min}^{-1}$   
 $k_4 = 0.06 \text{ min}^{-1}$

26

rest MBF (ml/min/g)  
 stress MBF (ml/min/g)  
 MFR (stress:rest)

MFR normal  $> 2.5$   
 MFR pathological  $< 2.0$



$$\frac{dC_t(t)}{dt} = K_1 \cdot C_a(t) - k_2 \cdot C_t(t)$$

$$C_t(t) = K_1 e^{-k_2 t} \otimes C_a(t)$$





# Broad Applicability / No Absolute Contraindications



$^{13}\text{N}$ -ammonia PET/CT



# Superior Image Quality (at lower radiation dose)



NH3-PET

5.0 mSv

1.03 mSv






Male patient, 80y, BMI 23kg/m<sup>2</sup>

A picture is worth a thousand words


But if you add numbers...

you get to see the «hidden side»


48-year old female  
atypical angina  
CACs 82, non-obstructive on CCTA



# High Reproducibility – Ideal for Follow-Up in Complex Situations




06/2018



12/2020



Recurrent  
typical angina



03/2024



NSTEMI  
hypertensive  
situation

# Routine Calcium Scoring




# Small Vessels – Large Impact

## Role of Coronary Microvascular Dysfunction Across Different Cardiovascular Diseases



# PET is Ideal for Assessing the Macro- and Microcirculation



# Microvascular Disease is Prevalent

## Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis


Niya Mileva <sup>1</sup>, MD; Sakura Nagumo, MD, PhD; Takuya Mizukami <sup>2</sup>, MD, PhD; Jeroen Sonck, MD; Colin Berry <sup>3</sup>, MD, PhD; Emanuele Gallinoro <sup>4</sup>, MD; Giovanni Monizzi, MD; Alessandro Candrea, MD; Daniel Munhoz <sup>5</sup>, MD, PhD; Dobrin Vassilev, MD, PhD; Martin Penicka, MD, PhD; Emanuele Barbato <sup>6</sup>, MD, PhD; Bernard De Bruyne <sup>7</sup>, MD, PhD; Carlos Collet <sup>8</sup>, MD, PhD

14427 patients with no obstructive CAD

Among noninvasive methods, a higher rate of CMD was found in patients who underwent PET compared with other modalities

(0.46 [95% CI, 0.46–0.65]) vs. (0.40 [95% CI, 0.30–0.55]; p=0.019)

Pooled prevalence of CMD  
0.41 [95% CI, 0.36–0.47]



# Quantitativ vs. Semi-quantitativ

## Leaving Relativity Behind

Quantitative Clinical Perfusion Imaging\*

Frank M. Bengel, MD

*Hannover, Germany*

### EDITORIAL COMMENT

Absolute Figures Are Better Than Percentages\*


Paolo G. Camici, MD

*London, United Kingdom*

JACC: CARDIOVASCULAR IMAGING  
© 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER INC.

VOL. 2, NO. 6, 2009  
ISSN 1936-878X/09/536.00  
DOI:10.1016/j.jcmg.2009.04.005

# Performance to rule in or rule out obstructive CAD



# So which modality should we use in clinical routine?

28'664 patients from 132 studies

## The performance of different tests for anatomically significant CAD


<b>Anatomically significant CAD</b>				
<b>Test</b>	<b>Sensitivity (%), (95% CI)</b>	<b>Specificity (%), (95% CI)</b>	<b>+LR (95% CI)</b>	<b>-LR (95% CI)</b>
Stress ECG	58 (46–69)	62 (54–69)	1.53 (1.21–1.94)	0.68 (0.49–0.93)
Stress echo	85 (80–89)	82 (72–89)	4.67 (2.95–7.41)	0.18 (0.13–0.25)
CCTA	97 (93–99)	78 (67–86)	4.44 (2.64–7.45)	0.04 (0.01–0.09)
SPECT	87 (83–90)	70 (63–76)	2.88 (2.33–3.56)	0.19 (0.15–0.24)
PET	90 (78–96)	85 (78–90)	5.87 (3.40–10.15)	0.12 (0.05–0.29)
Stress CMR	90 (83–94)	80 (69–88)	4.54 (2.37–8.72)	0.13 (0.07–0.24)

# Diagnostic Performance

**META-ANALYSIS**


## The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability

Juhani Knuuti<sup>1\*</sup>, Haitham Ballo<sup>1†</sup>, Luis Eduardo Juarez-Orozco<sup>1†</sup>, Antti Saraste<sup>1</sup>,  
 Philippe Kolh<sup>2</sup>, Anne Wilhelmina Saskia Rutjes<sup>3</sup>, Peter Jüni<sup>4</sup>, Stephan Windecker<sup>5</sup>,  
 Jeroen J. Bax<sup>6</sup>, and William Wijns<sup>7</sup>







# A Personalized Approach To Evaluating CAD


Modified from  
Buechel RR. Swiss Medical Weekly, 2019  
Buechel RR. Dt. Aerzteblatt. 2020




# Clinical and Cost Effectiveness

Data from EVINCI study  
n=350  
Endpoint: 50% stenosis at ICA





# CAC score percentiles specific for Switzerland – CH-CACS



Distribution of coronary artery calcium in a large European all-comer population referred for cardiac imaging

Julia Duelli, Christoph Ryffel, Magdalena Stuetz, Raffael Ghenzi, Marko Gajic, Dimitrios Moysidis, Dominik C. Benz, Aju P. Pazhenkottil, Andreas A. Giannopoulos, Philipp A. Kaufmann, Ronny R. Buechel

Department of Nuclear Medicine, Cardiac Imaging, University and University Hospital of Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland

**Swiss population**  
**n = 18'225**



[www.cardiacimaging.ch/cacs](https://www.cardiacimaging.ch/cacs)

## CACS Percentile Calculator

Sex:

Male

Female

Age:

65

CACS:


123

Submit

Result:





Percentile: 76  
Median CACS: 16

## CACS Percentile Plot:



# Vor- und Nachteile

# Coronary CT Angiography (CCTA)



Giannopoulos AA & Buechel RR. J Nucl Cardiol. 2019 Feb;26(1):141-153.

## Advantages

- Widely available
- Fast (<30min)
- Excellent sensitivity (High NPV)
- Very low radiation dose exposure (<1mSv)
- Assessment of plaque composition

## Disadvantages

- Pt preparation necessary (BB, Nitro)
- Pts with arrhythmias and tachycardia remain challenging
- Modest specificity (Low PPV)